| Defining the KRAS-and ERK-dependent transcriptome in KRAS-mutant cancers JA Klomp, JE Klomp, CA Stalnecker, KL Bryant, AC Edwards, ... Science 384 (6700), eadk0775, 2024 | 3 | 2024 |
| Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study … KH Lim, KR Spencer, RA Safyan, VJ Picozzi, AM Varghese, D Siolas, ... Journal of Clinical Oncology 42 (16_suppl), 4140-4140, 2024 | | 2024 |
| Allele-specific KRAS mutations as prognostic biomarkers in mucinous adenocarcinoma of the appendix and colorectal cancer. MM Khushman, HM Abushukair, S Alhushki, M Iglesia, KH Lim, X Liu, ... Journal of Clinical Oncology 42 (16_suppl), 3628-3628, 2024 | | 2024 |
| Molecular insights into oxaliplatin-induced peripheral neuropathy in colorectal cancer: Unraveling a potential signature. S Modekurty, M Iglesia, KS Pedersen, C Salvador, S Haroutounian, ... Journal of Clinical Oncology 42 (16_suppl), e15506-e15506, 2024 | | 2024 |
| Abstract CT130: Epacadostat with preoperative chemoradiation in locally advanced rectal cancer (LARC): Results of a translational phase I clinical trial H Park, K Pedersen, K Huang, M Mutch, H Kim, N Trikalinos, O Aranha, ... Cancer Research 84 (7_Supplement), CT130-CT130, 2024 | | 2024 |
| Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer A Bulle, P Liu, K Seehra, S Bansod, Y Chen, K Zahra, V Somani, ... Nature Communications 15 (1), 2503, 2024 | 2 | 2024 |
| Research and Clinical Updates on IRAK4 and Its Roles in Inflammation and Malignancy: Themes and Highlights from the 1st Symposium on IRAK4 in Cancer G Garcia-Manero, U Platzbecker, KH Lim, G Nowakowski, ... Frontiers in Hematology 3, 1339870, 2024 | 2 | 2024 |
| Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Y Wu, S Chen, X Yang, K Sato, P Lal, Y Wang, AT Shinkle, MC Wendl, ... Cancer research 83 (24), 4161-4178, 2023 | | 2023 |
| Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma X Zhang, L Detering, GS Heo, D Sultan, H Luehmann, L Li, V Somani, ... ACS Pharmacology & Translational Science 7 (1), 285-293, 2023 | | 2023 |
| A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy PM Grierson, R Suresh, B Tan, KS Pedersen, M Amin, H Park, ... Clinical Cancer Research 29 (23), 4733-4739, 2023 | | 2023 |
| Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study A Wang-Gillam, KH Lim, R McWilliams, R Suresh, AC Lockhart, A Brown, ... Clinical Cancer Research 29 (22), 4698-4698, 2023 | | 2023 |
| High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival EP Storrs, P Chati, A Usmani, I Sloan, BA Krasnick, R Babbra, PK Harris, ... npj Precision Oncology 7 (1), 105, 2023 | 4 | 2023 |
| Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology UY Panni, MY Chen, F Zhang, DR Cullinan, L Li, CA James, X Zhang, ... Cancer Immunology, Immunotherapy 72 (8), 2813-2827, 2023 | 1 | 2023 |
| A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy. P Grierson, R Suresh, BR Tan, KS Pedersen, MA Amin, H Park, ... Journal of Clinical Oncology 41 (16_suppl), e16263-e16263, 2023 | | 2023 |
| STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations. M Iglesia, MM Khushman, KH Lim, BA Van Tine, J Liu, KS Pedersen, ... Journal of Clinical Oncology 41 (16_suppl), 2619-2619, 2023 | | 2023 |
| Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with … LK Park, KH Lim, J Volkman, M Abdiannia, H Johnston, Z Nigogosyan, ... Cancer & Metabolism 11 (1), 6, 2023 | 8 | 2023 |
| High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival A Chaudhuri, E Storrs, P Chati, A Usmani, I Sloan, B Krasnick, RK Babbra, ... | | 2023 |
| TRIM4 is the E3 ubiquitin-ligase for TPL2/MAP3K8 and is modulated by oncogenic KRAS SP Bansod, PB Dodhiawala, A Bulle, P Liu, L Li, PM Grierson, J Held, ... Cancer Research 83 (7_Supplement), 2620-2620, 2023 | | 2023 |
| TNF-MK2 signaling drives protective autophagy following MAPK pathway inhibition in pancreatic cancer IA Khawar, Q Wei, THP Chen, L Lin, PM Grierson, KH Lim Cancer Research 83 (7_Supplement), 3870-3870, 2023 | | 2023 |
| Compositions and methods for the treatment of pancreatic cancer KH Lim, P Grierson US Patent App. 17/908,863, 2023 | | 2023 |
